BMS Reports the EMA’s Validation of the Application for Subcutaneous Opdivo
Shots:
- The EMA has validated the application to introduce an SC form of Opdivo with a new strength (600mg/vial) for various solid tumors as monotx. or in combinations, supported by the P-III (CheckMate -67T) trial
- The P-III (CheckMate -67T) trial investigates the co-formulation of Opdivo & recombinant human hyaluronidase (rHuPH20) known as SC Opdivo vs IV Opdivo in advanced/metastatic clear cell renal cell carcinoma (ccRCC) patients previously treated with systemic therapy
- The study depicted superiority in 1EPs of Cavgd28 (time-averaged Opdivo serum concentration over 28 days) & Cminss (trough serum concentration at steady state) as well as in 2EP of ORR with a consistent safety profile. Data was highlighted at ASCO GU & ASCO 2024
Ref: BMS | Image: BMS
Related News:- BMS Features the P-III (CheckMate -9DW) Trial Data of Opdivo Plus Yervoy for Treating Advanced Hepatocellular Carcinoma at ASCO 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
